Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 16Head & Neck 3Gynecologic 3Genitourinary 3Thoracic 2Breast 2Sarcoma 1Dermatologic 1CNS 1

Conditions

Sarcoma 11Neoplasms 5Sarcoma, Ewing 4Pancreatic Neoplasms 4Rhabdomyosarcoma 3Osteosarcoma 3Breast Neoplasms 3Recurrence 2Neuroblastoma 2Neoplasm Metastasis 2Melanoma 2Colorectal Neoplasms 2Wilms Tumor 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Rectal Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms, Germ Cell and Embryonal 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Leukemia-Lymphoma, Adult T-Cell 1Kidney Neoplasms 1Histiocytoma 1Hereditary Sensory and Autonomic Neuropathies 1Hepatoblastoma 1Hemangiosarcoma 1Gliosarcoma 1Glioma 1Glioblastoma 1

Interventions

Cyclophosphamide 5Fluorouracil 4pembrolizumab 3fludarabine 3Gemcitabine 3Docetaxel 3Cisplatin 3belinostat 2Quality of Life 2Psychiatric Rehabilitation 2Oxaliplatin 2Observation 2Leucovorin 2Irinotecan 2Filgrastim 2Erlotinib Hydrochloride 2Drug Therapy 2Cetuximab 2Carboplatin 2Blood Specimen Collection 2Bevacizumab 2130-nm albumin-bound paclitaxel 2umbralisib 1trifluridine tipiracil drug combination 1trastuzumab deruxtecan 1toripalimab 1seribantumab 1rucaparib 1resiquimod 1poly ICLC 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Albumin-Bound Paclitaxel × Sarcoma × Clear all
NCT02574663 2019-10-02

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

TG Therapeutics, Inc.

Phase 1 Completed
66 enrolled
GastrointestinalSarcoma

Esophageal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡